Biotechnology | Chemical | FDA | Life Science News | NIH | Radiology | Therapeutics
HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development of its Oral Decorporation Agent for Heavy Metal Toxicity
On Oct. 28, 2024, HOPO Therapeutics announced that it has been awarded a contract valued at up to…